Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug Use-Results Survey of OPDIVO in Cancer of Unknown Primary
jRCT2041240121Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in cancer of unknown primary (CUP), sponsored by Ono Pharmaceutical. Primary endpoints: Occurrence status of adverse drug reactions and infections and Adverse events. Started Jul 2022; status: completed.
02
Drugs
03
Conditions
cancer of unknown primary (CUP)
Beyond the preview
Go deeper on jRCT2041240121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240121.